Evaluating microRNAs for diagnosing testicular cancer in small masses.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the diagnostic effectiveness of circulating microRNAs in identifying germ cell cancer in patients with small testicular masses or retroperitoneal residual masses following chemotherapy. The study includes two cohorts: one with patients suitable for testis-sparing surgery and another with patients eligible for retroperitoneal lymph node dissection. Participants must be adults with specific criteria regarding tumor size and serum tumor markers. The findings could enhance diagnostic accuracy and treatment planning for testicular cancer patients.

Why it matters

Who can join: the full rules

COHORT A:

Inclusion Criteria:

* Age \>= 18 years
* Single testicular lesion, with \< 2 cm diameter and \< 30 % testicular volume involvement;
* Negative Serum Tumour Markers;
* Suitable for testis sparing surgery;
* Informed consent.

Exclusion Criteria:

* None

COHORT B:

Inclusion Criteria:

* Age \>= 18 years
* Single/multiple post-chemotherapy retroperitoneal lymph node lesion, with \> 1 cm (non seminomatous) / \> 3 cm (seminomatous) diameter in patients with previous testicular germ cell primary tumour;
* Negative Serum Tumour Markers;
* Suitable for retroperitoneal lymph node dissection;
* Informed consent.

Exclusion Criteria:

* None

Where it's running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna Policlinico di S. Orsola
  Bologna, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Primary retroperitoneal lymph node surgery versus chemotherapy for good‑prognosis metastatic testicular cancer

  This study will test whether primary RPLND (surgery) instead of standard chemotherapy leads to fewer side effects and better quality of life for men 18 and older with good‑prognosis metastatic testicular cancer.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Göteborg · NCT07498959

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

• Navigation program for young cancer survivors

  This project tests an adapted navigation program to help adolescent and young adult cancer survivors get timely care within Kaiser Permanente Southern California.

  Recruiting Kaiser Permanente · Pasadena, California · NCT07406087

• Testing trastuzumab deruxtecan (T‑DxD) for HER2‑positive advanced solid tumors

  This will test whether trastuzumab deruxtecan (T‑DxD) helps adults in the US with HER2‑positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have had prior systemic treatment and have no satisfactory alternative options.

  Recruiting at 18 sites AstraZeneca · Birmingham, Alabama and 17 other locations · NCT07124000

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• How retroperitoneal lymph node dissection affects urination and sexual function

  This project will see if retroperitoneal lymph node dissection (RPLND) for testicular cancer changes urination, ejaculation, erections, and quality of life in adult men.

  Recruiting Jagiellonian University · Krakow, Malopolska · NCT06954233

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.